The effect of the bisphosphonate alendronate on viability of canine osteosarcoma cells in vitro

  • James P. Farese
  • Jenna Ashton
  • Rowan Milner
  • Linda-Lee Ambrose
  • James van Gilder
Articles Cell Growth/Differentiation/Apoptosis


The objective of this study was to determine the effect of alendronate on the viability of canine osteosarcoma cells and nonneoplastic canine cells. The sample population was composed of canine osteosarcoma tumor cells. Osteosarcoma cells and canine fibroblasts were maintained in culture under standard conditions. The MTT assay for cell viability was performed after 24, 48, and 72 h of incubation with alendronate (0.001 to 1000 μM) or no drug (control). Plates were set up so that each concentration and the control had a sample number of 8. The optical density (OD) of each well was measured at 540 nm using an enzyme-linked immunosorbent assay microplate reader. The percent viability was determined for each concentration and for each incubation time. After 24 h of incubation of POS (parent osteosarcoma) and HMPOS cells with alendronate, there was no significant difference in mean OD at any drug concentration when compared with control samples. A significant concentration- and time-dependent reduction in mean OD of osteosarcoma cells was observed after 48 and 72 h of incubation, with alendronate concentrations ranging from 10 to 1000 μM. The lowest percent cell viability observed in treated cells was 35%. Conversely, alendronate did not significantly affect mean OD in fibroblasts, and the lowest percent cell viability observed was 76%. Our data indicate that alendronate may have the potential to inhibit canine osteosarcoma tumor growth. It will be important to determine the clinical relevance of these in vitro findings. If similar findings are observed in vivo, use of alendronate may also be indicated as an adjuvant to existing chemotherapeutic protocols.

Key words

canine osteosarcoma bisphosphonate alendronate 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Andela, V. B.; Rosesnblatt, J. D.; Schwarz, E. M., et al. Synergism of aminobisphosphonates and farnesyl transferase inhibitors on tumor metastasis. Clin. Orthop. 397:228–239; 2002.PubMedCrossRefGoogle Scholar
  2. Barroga, E. F.; Kadosawa, T.; Okumura, M., et al. Establishment and characterization of the growth and pulmonary metastasis of a highly metastasizing cell line from canine osteosarcoma in nude mice. J. Vet. Med. Sci. 61:361–367; 1999.PubMedCrossRefGoogle Scholar
  3. Berg, J. Canine osteosarcoma amputation and chemotherapy. Vet. Clin. North Am. Small Anim. Pract. 26:111–121; 1996.PubMedGoogle Scholar
  4. Bone, H. G.; Adami, S.; Rizzoli, R., et al. Weekly administration of alendronate: rationale and plan for clinical assessment. Clin. Ther. 22:15–28; 2000.PubMedCrossRefGoogle Scholar
  5. Coleman, R. E. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat. Rev. 27:165–176; 2001.PubMedCrossRefGoogle Scholar
  6. Dernell, W. S.; Straw, R. C.; Withrow, S. J. Tumors of the skeletal system. In: Withrow, S. J.; Straw, R. C., ed. Small animal clinical oncology. 3rd ed. Philadelphia, PA: W. B. Saunders: 2001:378–417.Google Scholar
  7. Fisher, J. E.; Rogers, M. J.; Halasy, J. M., et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc. Natl. Acad. Sci. USA 96:133–138; 1999.PubMedCrossRefGoogle Scholar
  8. Fromigue, O.; Lagneaux, L.; Body, J. J. Bisphosphonates induce breast cancer cell death in vitro. J. Bone Miner. Res. 11:2211–2221; 2000.CrossRefGoogle Scholar
  9. Gertz, B. J.; Holland, S. D.; Kline, W. F., et al. Studies of the oral bioavailability of alendronate. Clin. Pharm. Therap. 58:288–297; 1995.PubMedCrossRefGoogle Scholar
  10. Giuliani, N.; Pedrazzoni, M.; Negri, G., et al. Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo. Bone 22:455–461; 1998.PubMedCrossRefGoogle Scholar
  11. Green, J. R. Antitumor effects of bisphosphonates. Cancer Suppl. 97:840–847; 2003.Google Scholar
  12. Halasy-Nagy, J. M.; Rodan, G. A.; Reszka, A. A. Keratinocyte model for bisphosphanate esophageal irritation: inhibition of cell growth by combined inhibition of protein prenylation and sterol synthesis. J. Bone Miner. Res. 14:S406; 1999.CrossRefGoogle Scholar
  13. Kadosawa, T.; Nozaki, K.; Sasaki, N., et al. Establishment and characterization of a new canine cell line from a canine osteosarcoma. J. Vet. Med. Sci. 56:1167–1169; 1994.PubMedGoogle Scholar
  14. Lin, J. H.; Duggan, D. E.; Chen, I. W., et al. Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals. Drug. Metab. Dispos. 19:375–388; 1991.Google Scholar
  15. Luckman, S. P.; Hughes, D. E.; Coxon, F. P., et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J. Bone Miner. Res. 13:581–589; 1998.PubMedCrossRefGoogle Scholar
  16. Mackie, P. S.; Fisher, J. L.; Zhou, H., et al. Bonphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. Br. J. Cancer. 84:951–958; 2001.PubMedCrossRefGoogle Scholar
  17. Morello, L.; Buracco, P.; Martano, M., et al. Bone allografts and adjuvant cisplatin for the treatment of canine appendicular osteosarcoma in 18 dogs. J. Small Anim. Pract. 42:61–65; 2001.PubMedGoogle Scholar
  18. O'Brien, M.; Withrow, S. J.; Straw, R. C. Recent advances in the treatment of canine appendicular osteosarcoma. Compend. Contin. Educ. Pract. Vet. 15:939–945; 1993.Google Scholar
  19. Peter, C. P.; Cook, W. O.; Nunamaker, D. M., et al. Effect of alendronate on fracture healing and bone remodeling in dogs. J. Orthop. Res. 14:74–79; 1996.PubMedCrossRefGoogle Scholar
  20. Porras, A. G.; Holland, S. D.; Gertz, B. J. Pharmacokinetics of alendronate. Clin. Pharmacokinet. 36:315–328; 1999.PubMedCrossRefGoogle Scholar
  21. Rodan, G. A. Mechanisms of action of bisphosphonates. Annu. Rev. Pharmacol. Toxicol. 38:375–388; 1998.PubMedCrossRefGoogle Scholar
  22. Rogers, M. J.; Gordon, S.; Benford, H. L., et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88:2961–2978; 2000.PubMedCrossRefGoogle Scholar
  23. Sato, M.; Grasser, W.; Endo, N., et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J. Clin. Invest. 88:2095–2105; 1991.PubMedCrossRefGoogle Scholar
  24. Senaratne, S. G.; Pirianov, G.; Mansi, J. L., et al. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br. J. Cancer. 82:1459–1468; 2000.PubMedGoogle Scholar
  25. Shinoda, H.; Adamek, G.; Felix, R., et al. Structure-activity relationships of various bisphosphonates. Calcif. Tissue Int. 35:87–99; 1993.CrossRefGoogle Scholar
  26. Shipman, C. M.; Rogers, M. J.; Apperley, J. F., et al. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumor activity. Br. J. Haematol. 98:665–672; 1997.PubMedCrossRefGoogle Scholar
  27. Sonnemann, J.; Eckervogt, V.; Truckenbrod. B., et al. The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro. Anticancer Drugs 12:459–465; 2001.PubMedCrossRefGoogle Scholar
  28. Stodnick, G. J.; Berg, J.; Rand, W. M., et al. Prognosis for dogs with appendicular osteosarcoma treated by amputation alone: 162 cases (1978–1988). J. Am. Vet. Med. Assoc. 200:995–998; 1992.Google Scholar
  29. Stearns, M. E.; Wang, M. Alendronate blocks metalloproteinase secretion in bone collagen I release by PC-3 ML cells in SCID mice. Clin. Exp. Metastasis 16:693–702; 1998.PubMedCrossRefGoogle Scholar
  30. Theriault, R. L.; Hortobagyi, G. N. The evolving role of bisphosphonates. Semin. Oncol. 28:284–290; 2001.PubMedCrossRefGoogle Scholar
  31. Tomlin, J. L.; Sturgeon, C.; Pead, M. J., et al. Use of the bisphosphonate drug alendronate for palliative management of osteosarcoma in two dogs. Vet. Rec. 147:129–132; 2001.Google Scholar

Copyright information

© Society for In Vitro Biology 2004

Authors and Affiliations

  • James P. Farese
    • 1
  • Jenna Ashton
    • 1
  • Rowan Milner
    • 1
  • Linda-Lee Ambrose
    • 1
  • James van Gilder
    • 1
  1. 1.Department of Small Animal Clinical Sciences, College of Veterinary MedicineUniversity of FloridaGainesville

Personalised recommendations